The High Sensitivity of the Multi-Cancer Detection Test ONCOVERYX-F Offers a Promising Platform for Ovarian Cancer Screening

Figures & data

Table 1 The Sample Set Employed for the Study

Sample Type	Ethnicity	No. of Samples in Age Groups (yrs)				Total No.
		20–40	41–60	61–80	>80
OvC	Cau	47	90	46	3	186
	SA/I	39	111	31	3	184
NoC	Cau	69	179	50	0	298
	SA/I	150	170	113	0	433

Notes: The table provides a summary of the ovarian cancer (OvC) and normal control (NoC) samples, and their distribution between Caucasians (Cau) and South Asians/Indians (SA/I) in the different age groups as indicated.

Figure 1 STARD diagram to report flow of participants through the study.

Figure 2 A comparison of the efficacies of OncoVeryx-F and CA 125-based testing for OvC detection. (A) Shows the confusion matrix generated from the y-scores estimated by OncoVeryx-F for the individual OvC and NoC samples. The sensitivity obtained was 98.6% (96.41, 100) at 95% CI, at a specificity of 99.03% (97.08, 100) at 95% CI, and the accuracy was 98.85% (97.32, 100) at 95% CI. (B) Shows the corresponding matrix obtained when OvC versus NoC discrimination was derived on the basis of the CA 125 cut-off level of 35 U/mL. The sensitivity and specificity obtained in each case is also given here.

Figure 3 Ethnicity-dependence of the performance of CA 125 and OncoVeryx-F for OvC detection. Shows the distribution of CA 125 concentrations in samples from the OvC and NoC groups in both Caucasian and South Asian/Indian women.

Table 2 Ethnicity-Dependant OvC-Detection Accuracy of CA 125 and OncoVeryx-F Test

Ethnicity	CA 125		OncoVeryx-F
	Sensitivity	Specificity	Sensitivity	Specificity
Cau	83.7%	92.8%	98.5%	98.3%
SA/I	32.8%	93.3%	98.9%	99.5%

Notes: The table provides a summary of the Sensitivity and Specificity of OvC detection obtained in both Caucasians (Cau) and South Asians/Indians (SA/I) women when either the CA 125 biomarker or OncoVeryx-F was used.

Figure 4 Comparative efficacy of Stage I OvC detection by OncoVeryx-F and CA 125. Shown here are the confusion matrices obtained for detection of Stage I OvC samples using either OncoVeryx-F (A) or CA 125 (B) as the test system.

Data Sharing Statement

Individual deidentified participant data will be available for six months from date of publication of the corresponding author.